Literature DB >> 19646894

Porphyrin synthesis from aminolevulinic acid esters in endothelial cells and its role in photodynamic therapy.

Lorena Rodriguez1, Henriëtte S de Bruijn, Gabriela Di Venosa, Leandro Mamone, Dominic J Robinson, Angeles Juarranz, Alcira Batlle, Adriana Casas.   

Abstract

Photodynamic therapy (PDT) may cause tumour cell destruction by direct toxicity or by inducing microcirculatory shutdown. Protoporphyrin IX generated from 5-aminolevulinic acid (ALA) has been widely used as an endogenous photosensitiser in PDT. However, the hydrophilic nature of the ALA molecule limits its penetration through the stratum corneum of the skin and cell membranes and thus, ALA alkyl-esters have been developed to improve ALA permeation. The aim of this work was to study Protoporphyrin IX synthesis from ALA and its derivatives ALA methyl ester (Me-ALA) and ALA hexyl ester (He-ALA) in the microvascular endothelial cell line HMEC-1 derived from normal skin, and to evaluate their response to PDT. We found that lower light doses are required to photosensitise HMEC-1 endothelial cells than to photosensitise PAM212 transformed keratinocytes, showing some possible selectivity of ALA-PDT for vascularisation in skin. Employed at concentrations leading to equal Protoporphyrin IX synthesis, ALA, He-ALA and Me-ALA presented the same efficacy of HMEC-1 photosensitisation. However, He-ALA was a promising compound for the use in the enhancement of Protoporphyrin IX in HMEC-1 cells employed at low concentrations at both short and long time exposures whereas Me-ALA should be employed at high concentrations and longer time periods in order to surpass the Protoporphyrin IX levels obtained with ALA. The advantage of Me-ALA over ALA was based on its lower dark toxicity. This is the first work to report vascular cell photosensitisation employing alkyl-esters of ALA, and we demonstrated that these derivatives could exert the same effect as ALA and under certain conditions enhance photosensitisation of vasculature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646894     DOI: 10.1016/j.jphotobiol.2009.07.001

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  9 in total

1.  Vascular alterations after photodynamic therapy mediated by 5-aminolevulinic acid in oral leukoplakia.

Authors:  Flávia Cristina Perillo Rosin; Ana Rita Ribeiro Barcessat; Giuliana Gadoni Giovanni Borges; Luciana Gonçalves Valente Ferreira; Luciana Corrêa
Journal:  Lasers Med Sci       Date:  2016-12-21       Impact factor: 3.161

2.  Activating Photodynamic Therapy in vitro with Cerenkov Radiation Generated from Yttrium-90.

Authors:  Brad A Hartl; Henry Hirschberg; Laura Marcu; Simon R Cherry
Journal:  J Environ Pathol Toxicol Oncol       Date:  2016       Impact factor: 3.567

3.  Photodynamic therapy for periungual pyogenic granuloma-like during chemotherapy: our preliminary results.

Authors:  G Fabbrocini; M C Annunziata; M Donnarumma; S Cacciapuoti; C Marasca; A Tosti
Journal:  Support Care Cancer       Date:  2018-02-10       Impact factor: 3.603

4.  Pyogenic granuloma in a patient with psoriasis successfully treated by 5-aminolevulinic acid photodynamic therapy: A case report.

Authors:  Juan Liu; Bing-Rong Zhou; Fei Yi; Hong-Jin Wu; Jia-An Zhang; Dan Luo
Journal:  Exp Ther Med       Date:  2015-11-27       Impact factor: 2.447

5.  Comparison of Kinetic Study and Protective Effects of Biological Dipeptide and Two Porphyrin Derivatives on Metal Cytotoxicity Toward Human Lymphocytes.

Authors:  Maryam Khosravi; Rahmatollah Rahimi; Jalal Pourahmad; Mohammad Hadi Zarei; Mahboubeh Rabbani
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

Review 6.  Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery?

Authors:  Katsuyuki Kusuzaki; Takao Matsubara; Hiroaki Murata; Mariantonia Logozzi; Elisabetta Iessi; Rossella Di Raimo; Fabrizio Carta; Claudiu T Supuran; Stefano Fais
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

7.  Topical Photodynamic Therapy with Different Forms of 5-Aminolevulinic Acid in the Treatment of Actinic Keratosis.

Authors:  Joanna Bartosińska; Paulina Szczepanik-Kułak; Dorota Raczkiewicz; Marta Niewiedzioł; Agnieszka Gerkowicz; Dorota Kowalczuk; Mirosław Kwaśny; Dorota Krasowska
Journal:  Pharmaceutics       Date:  2022-02-01       Impact factor: 6.321

8.  Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.

Authors:  Ana Luiza Ribeiro de Souza; Kayla Marra; Jason Gunn; Kimberley S Samkoe; Stephen Chad Kanick; Scott C Davis; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Br J Cancer       Date:  2016-08-30       Impact factor: 7.640

9.  Probing Hexaminolevulinate Mediated PpIX Fluorescence in Cancer Cell Suspensions in the Presence of Chemical Adjuvants.

Authors:  Kit Man Chan; Jonathan Gleadle; Krasimir Vasilev; Melanie MacGregor
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.